Recursion Pharmaceuticals Inc (RXRX) Quote

Was only a matter of time before another company jumped on the bandwagon:

"Dell Technologies and Northwestern Medicine to Advance Patient Care through AI Innovation"

https://www.prnewswire.com/news-releases/dell-technologies-and-northwestern-medicine-to-advance-patient-care-through-ai-innovation-302108735.html

RXRX under $10

Joe of Nanolyze explains RXRX

RXRX 10Q 2/27

In a 100 trilliona biology yes

Looks like 5 dollars is a good buy

RXRX will that awful Cathie Wood keep buying

So the Bayer collaboration just pivoted from Fibrosis to Oncology after three years of effort. The good news is the milestones are bigger than the prior indication. The bad news seems to be that AI won't be able to tackle some of the hardest diseases like fibrosis effectively. I would like to see a broadening of partners, and clearly so does the street. And while we have funding to get through 2024, we need higher stock prices to effectively raise capital under the current ATM filing.

RXRX
Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Previous close $5.91 +$0.68 (+13.00%)

Today $6.05 +0.14 (+2.37%) Pre-Market

Volume 11,004

Link back for my notes https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173148805

2 Reasons to Buy Recursion Pharmaceuticals, and 1 Reason to Sell
By Alex Carchidi – Oct 31, 2023 for The Motley Fool

https://stockcharts.com/h-sc/ui?s=RXRX

KEY POINTS
Recursion is forging key relationships with powerful collaborators.
The young biotech's valuation is also looking a lot better now.
However, its finances are nowhere near breakeven yet.

NASDAQ: RXRX
Recursion Pharmaceuticals
Market Cap
$1B
Today's Change
(13.00%) $0.68
Current Price
$5.91
Price as of November 3, 2023, 4:00 p.m. ET

Pioneering businesses tend to carry big risks, but also the potential for big rewards.
Discovering new drugs is no easy task, and one young company that aims to help in that process is Recursion Pharmaceuticals (RXRX 13.00%). Though it still hasn't brought a product to market just yet, it's begun to receive some attention already for its innovative approach -- and so now is a good time to consider its merits and risks as a long-term investment.

In particular, there are two main reasons to think about buying Recursion, and one key reason to sell or avoid buying it. Let's start with the big-picture view of why it's worthwhile.

Buy: It'll give you exposure to AI in the healthcare sector
It's probably a good idea to have at least some exposure to the healthcare sector in your portfolio. The same goes for artificial intelligence (AI) stocks, and Recursion Pharmaceuticals fits in both those niches quite nicely. It's seeking to develop an AI platform to help guide drug discovery and selection of therapy candidates; its goals are to lower costs and time spent on the drug development process, and to reduce the risk of expensive late-stage pre-clinical or clinical failures.

With that platform in hand, it plans to identify and test its own leads with the goal of eventually commercializing medicines developed in-house. Right now, it has three rare-disease programs in phase 2 trials as well as a pair of programs in phase 1. Those projects will need a few more years before they're ready for regulatory review.

In the meantime, Recursion is hoping to license its platform to the biopharma industry at large to generate some revenue. It already has buy-in from major pharmaceutical competitors like Bayer AG, with which it's collaborating to find leads for drugs to treat fibrosis. Such a vote of confidence isn't a reason to buy the stock on its own, but it's still a positive indicator for the future.

Buy: It's no longer priced at a huge premium
In July, Recursion inked a deal with Nvidia, the chipmaker and perhaps the most hyped AI stock. Nvidia invested $50 million in Recursion to secure its help in building a cloud-based generative AI service for drug discovery and development. The deal sent the biotech's stock flying overnight to an inflated price-to-sales (P/S) multiple near 60.

Since then, the hype surrounding Nvidia has continued, but Recursion's time in the spotlight has drawn to a close for now. Its shares are priced roughly the same as they were prior to the announcement and with a P/S ratio of about 20. So if you were bullish on the company's future before but were scared off by the prospect of overpaying for hyped-up shares, now's a better time to consider making a move.

Sell: Until its business model is validated, it's burning money
One thing that might encourage current investors to ditch shares of Recursion is that it hasn't proven yet its business model is actually viable. It lacks persuasive evidence for its core claims that its AI-based approach cuts research and development (R&D) expenditures, shortens pre-clinical timelines, and results in fewer late-stage failures. Investors who buy the stock now take on the risk that it won't be able to live up to those goals, which are vital to the company's long-term value.

Furthermore, with a net loss of $77 million in the second quarter, Recursion is nowhere near being profitable on the basis of its collaboration activities and sales of software licenses. Nor is it consistently adding to the top line with either segment; its quarterly revenue fell by more than 19% year over year in Q2, to a relatively paltry sum of $11 million. That means even if it has a few powerful collaborators in its corner, there isn't yet enough social proof to drive new customers to its platform in large numbers.

The company might continue to be unprofitable until shortly after it commercializes its first medicine, assuming that happens. Its $406 million of cash and equivalents should be sufficient to fund it through all of next year, and perhaps the first quarter of 2025. To continue operating after that, it'll need to take out a big loan, issue more shares, sign on another big collaborator, or meet one of the milestones for its existing collaborations.

Recursion will likely be able to find the funding it needs. But if that uncertainty bothers you, it's best to sell this stock, as there'll be even more uncertainty on the way for at least a few more years.

might have bottomed here

what happens after the furu's run it up

Adding some on dips

Next leg up soon

waiting for the reload

Icahn must be taking a stake. Someone is loading up. All dips being bought!

up up up

RXRX new 52 week high

RXRX Headed for a fifth high volume day
Quote as of 7/18/2023 10:07AM ET

https://stockcharts.com/h-sc/ui?s=RXRX

$13.88 +$0.48 +3.55%

Volume
3,731,978
90 Day Avg. Vol.
3,326,266

Open
$13.84
Previous Close 07/17/2023
$13.405

Day Range
Low$12.89
High$13.99

Could turn into a good trading stock

RXRX today

The stock I'm presently hanging out in.

https://stockcharts.com/h-sc/ui?s=RXRX

Huge volume, four days running

RECURSION PHARMACEUTICALS INC CL A
Quote AS OF 7/17/2023 4:00PM ET

$13.405 +$1.505 (+12.647%)

Volume
22,049,862

90 Day Avg. Vol.
3,087,700

Open
$11.72

Previous Close 07/14/2023
$11.90

Day Range
Low$11.60
High$14.32

Gap fill or not
We will know in the fullness of time

NVDA Trillion Dollar Company wants to invest $50 Million in a A1 Drug from RXRX are you kidding me!!?? This will shoot to $50+ in time. Partnering with NVDA This is Hidden GEM Moon time Coming! This will open a lot of Investors Interest and Eyes.

To those shorting RXRX.
This is Fr Gent, ihub's chaplain in residence.
I suggest you cover before the close, as it will only churn up more tomorrow.
Oh, you may not regret not doing so tonight. But you will tomorrow and forever.
Now cover and sin no more.

UPS strike in US could be costliest in at least a century
BY Lisa Baertlein, REUTERS

https://stockcharts.com/h-sc/ui?s=UPS

(Reuters) -A threatened U.S. strike at United Parcel Service ( UPS ) could be "one of the costliest in at least a century," a think tank specializing in the economic impact of labor actions said on Thursday.

Potential losses from a 10-day strike at the world's biggest package delivery company could top $7 billion, according to an estimate from Michigan-based Anderson Economic Group (AEG). That number includes UPS customer losses of $4 billion and lost direct wages of more than $1 billion.

(con't)

RXRX $12.95 +$0.87 (+7.16%)

The warden is jangling his keys- I may get an early release from bag holders prison.
I'm gonna tell him I want to stay. I don't want early release!

Volume
17,259,777 (hUge volume still)
90 Day Avg. Vol.
2,684,488

Previous Close 07/12/2023
$12.08
Day Range

Low$10.59
High$13.00

RXRX: My new system works!!! (God BLESS my ASK!!!!)

Okay wow!
as usual the shorts on the attack!
Thanks but I have to take a step to the side... so maybe it will go up more!
in a shitty market everything goes to shit sooner or later!
But they take away the desire to bet! It's now less risky at the casino!
You'll be able to take them lower...
over and out!

no 1 on the Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

Bezinga!!!!!!

Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
https://finance.yahoo.com/news/recursion-announces-collaboration-50-million-123000132.html

Yup right again

RXRX

Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery

Eleven bucks all over this imo

Nice ride

Why?
I sell ok
I'm satisfy!
then you wonder if there is a logic?
Thank you

Hit that one

Hmmmmm 8.23

8.65 bounce comin

Recursion Announces Collaboration With Roche And Genentech In Neuroscience And Oncology; Recursion To Receive $150M Upfront, Says Collaboration Could Yield $300M In Milestones And Royalties
7:58 am ET December 7, 2021 (Benzinga) Print
Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive innovation, today announced a transformational collaboration with Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Genentech, a member of the Roche Group. Recursion will work with both Roche and Genentech's R&D units to leverage technology-enabled drug discovery through the Recursion Operating System (OS) to more rapidly identify novel targets and advance medicines in key areas of neuroscience as well as in an oncology indication. Under the terms of the agreement, Recursion will receive an upfront payment of $150 million and is eligible for additional performance-based research milestones. Under the collaboration, Roche and Genentech (combined) may initiate up to 40 programs, each of which, if successfully developed and commercialized, could yield more than $300M in development, commercialization and net sales milestones for Recursion, as well as tiered royalties on net sales.